Patient demographics and clinical characteristics
| . | Overall . | GO1 . | GO2 . |
|---|---|---|---|
| N = 844 . | n = 422 . | n = 422 . | |
| Age, y, median (range) | 68 (50-81) | 67.5 (51-79) | 68 (50-81) |
| Age ≥65 y | 606 (72%) | 301 (71%) | 305 (72%) |
| Age ≥70 y | 283 (34%) | 141 (33%) | 142 (34%) |
| Male | 511 (61%) | 256 (61%) | 255 (60%) |
| WBC ×109/L median (range) | 5.8 (0.3-416.6) | 6.25 (0.3-416.6) | 5.65 (0.4-365) |
| <10 | 493 (58%) | 247 (59%) | 246 (58%) |
| ≥50 | 101 (12%) | 50 (12%) | 51 (12%) |
| Diagnosis | |||
| Clinical de novo AML | 673 (80%) | 338 (80%) | 335 (79%) |
| Clinical secondary AML | 89 (11%) | 44 (10%) | 45 (11%) |
| High-risk MDS | 82 (10%) | 40 (10%) | 42 (10%) |
| Performance ID (ECOG) | |||
| 0 | 404 (48%) | 202 (48%) | 202 (48%) |
| 1 | 386 (46%) | 193 (46%) | 193 (46%) |
| 2 | 54 (6%) | 27 (6%) | 27 (6%) |
| Genetic risk | |||
| Cytogenetic (Grimwade 2010) | |||
| Favorable | 30 (4%) | 22 (6%) | 8 (2%) |
| Intermediate | 558 (81%) | 277 (79%) | 281 (82%) |
| Adverse | 103 (15%) | 50 (14%) | 53 (16%) |
| Failed | 56 | 25 | 31 |
| Not reported | 97 | 48 | 49 |
| TP53+ | 69 (9%) | 32 (9%) | 37 (10%) |
| ELN 2017 | |||
| Favorable | 236 (33%) | 121 (33%) | 115 (32%) |
| Intermediate | 166 (23%) | 85 (23%) | 81 (23%) |
| Adverse | 323 (45%) | 160 (44%) | 163 (45%) |
| Unknown | 119 | 56 | 63 |
| ALFA 1200∗ | |||
| Go-go (favorable) | 274 (40%) | 140 (40%) | 134 (39%) |
| Slow-go (intermediate) | 360 (52%) | 180 (52%) | 180 (53%) |
| No-go (unfavorable) | 57 (8%) | 29 (8%) | 28 (8%) |
| Unknown | 153 | 73 | 80 |
| . | Overall . | GO1 . | GO2 . |
|---|---|---|---|
| N = 844 . | n = 422 . | n = 422 . | |
| Age, y, median (range) | 68 (50-81) | 67.5 (51-79) | 68 (50-81) |
| Age ≥65 y | 606 (72%) | 301 (71%) | 305 (72%) |
| Age ≥70 y | 283 (34%) | 141 (33%) | 142 (34%) |
| Male | 511 (61%) | 256 (61%) | 255 (60%) |
| WBC ×109/L median (range) | 5.8 (0.3-416.6) | 6.25 (0.3-416.6) | 5.65 (0.4-365) |
| <10 | 493 (58%) | 247 (59%) | 246 (58%) |
| ≥50 | 101 (12%) | 50 (12%) | 51 (12%) |
| Diagnosis | |||
| Clinical de novo AML | 673 (80%) | 338 (80%) | 335 (79%) |
| Clinical secondary AML | 89 (11%) | 44 (10%) | 45 (11%) |
| High-risk MDS | 82 (10%) | 40 (10%) | 42 (10%) |
| Performance ID (ECOG) | |||
| 0 | 404 (48%) | 202 (48%) | 202 (48%) |
| 1 | 386 (46%) | 193 (46%) | 193 (46%) |
| 2 | 54 (6%) | 27 (6%) | 27 (6%) |
| Genetic risk | |||
| Cytogenetic (Grimwade 2010) | |||
| Favorable | 30 (4%) | 22 (6%) | 8 (2%) |
| Intermediate | 558 (81%) | 277 (79%) | 281 (82%) |
| Adverse | 103 (15%) | 50 (14%) | 53 (16%) |
| Failed | 56 | 25 | 31 |
| Not reported | 97 | 48 | 49 |
| TP53+ | 69 (9%) | 32 (9%) | 37 (10%) |
| ELN 2017 | |||
| Favorable | 236 (33%) | 121 (33%) | 115 (32%) |
| Intermediate | 166 (23%) | 85 (23%) | 81 (23%) |
| Adverse | 323 (45%) | 160 (44%) | 163 (45%) |
| Unknown | 119 | 56 | 63 |
| ALFA 1200∗ | |||
| Go-go (favorable) | 274 (40%) | 140 (40%) | 134 (39%) |
| Slow-go (intermediate) | 360 (52%) | 180 (52%) | 180 (53%) |
| No-go (unfavorable) | 57 (8%) | 29 (8%) | 28 (8%) |
| Unknown | 153 | 73 | 80 |
ECOG, Eastern Cooperative Oncology Group; ALFA, Acute Leukemia French Association; MDS, myelodysplastic syndrome; WBC, white blood cell count.
Details of ALFA 1200 genetic score classification10 are provided in “Methods.”